Iclepertin: GlyT1 inhibitor
Phase 3
Indication: Cognitive impairment associated with schizophrenia (CIAS)
US FDA Breakthrough Therapy Designation
Iclepertin is an investigational asset and a GlyT1 inhibitor that targets the brain biology linked with the cognitive symptoms associated with schizophrenia (CIAS). Iclepertin may also provide benefits for cognitive impairment in other mental health conditions.
The cognitive impairments associated with schizophrenia (CIAS), such as trouble with problem solving, paying attention and memory, can have a large impact on the lives of people living with the condition, and subsequently on their families and care partners. CIAS is one particularly burdensome unmet need, along with positive and negative symptoms, that is unfortunately not addressed by current antipsychotics. CIAS is a highly impactful core symptom of schizophrenia that affects 80% of schizophrenia patients.
Our goal is to ease the significant burden of CIAS symptoms through the development of new therapies that can normalize brain dysfunction to enable individuals with schizophrenia to be more autonomous, have a more productive life, and regain positive social interactions.